The IPO Buzz: Iambic Therapeutics Priced at $16 – Mid-Point – & Gains 20 Percent on NASDAQ
Iambic Therapeutics(IAM) priced its IPO at $16.00 – the mid-point – and sold 9.38 million shares – the number in the prospectus – to raise $150 million on Wednesday night, Oct. 14. The Phase I cancer biotech’s stock edged higher in its NASDAQ debut - opening at $16.15 shortly after noon EDT on Thursday, Oct. 15, 2026. Iambic Therapeutics' stock gained steam and jumped 20 percent to t..
Read more October 14, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Amaero (Revived) | AMRO | 4.7 | $ 20.0 mil | 10/15/2026 Priced | S/O | S/O |
| Iambic Therapeutics | IAM | 9.4 | $ 150.0 mil | 10/15/2026 Priced | S/O | S/O |
| City Therapeutics | CTY | 9.7 | $ 175.0 mil | 10/16/2026 Friday | S/O | S/O |
Last 100 IPOs - October 14, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 39 |
| Number Down: | 59 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | -0.75% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 14, 2026
| Number of IPOs priced (Excluding 152 units) : | 130 |
| Number Up: | 48 |
| Number Down: | 80 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -1.73% |
| The Nasdaq Composite Index YTD % Change | 35.22% |